NCT01160237终止3 期
Immunogenicity and Safety of Fluarix™/ Influsplit SSW® 2010/2011 or Pandemrix™
适应症
试验速览
- 阶段
- 3 期
- 状态
- 终止
- 入组人数
- 7
- 试验地点
- 6
- 主要终点
- Humoral Immune Response in Terms of Haemagglutination Inhibition (HI) Antibodies for Each Vaccine Strain, in Subjects Aged 18-60 and Above 60 Years
研究概览
简要总结
The aim of this study is to evaluate the immune response and the safety of one injection of FluarixTM/ Influsplit SSW® 2010/2011 or Pandemrix TM in subjects who had received a single Pandemrix TM dose at least 6 months preceding study inclusion. Subjects never vaccinated with any H1N1 pandemic vaccine will be enrolled as control.
This Protocol Posting has been updated following Amendment of the Protocol, July 2010. The impacted section is entry criteria.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Subjects who the investigator believes can and will comply with the requirements of the protocol. Specific attention should be given to the compliance potential of subjects with suspected or known drug and alcohol abuse.
- •Subjects who have received one dose of Pandemrix at least 6 month before enrolment, to be enrolled in the Groups A or B OR subjects who have not been previously vaccinated with a vaccine against the pandemic H1N1 strain at all, to be enrolled in group C.
- •A male or female 18 years and above at the time of enrolment.
- •Written informed consent obtained from the subject.
- •Healthy subjects or free of acute aggravation of the health status as established by physical examination before entering into the study.
- •Female subjects of non-childbearing potential may be enrolled in the study.
- •Female subjects of childbearing potential may be enrolled in the study.
排除标准
- •Use of any investigational or non-registered product other than the study vaccine within 30 days preceding the dose of study vaccine, or planned use during the study period.
- •Administration of any influenza vaccine within 6 month prior to vaccination in this study.
- •Presence of evidence of substance abuse or of neurological or psychiatric diagnoses which, although stable, are deemed by the investigator to render the potential subject unable/unlikely to provide accurate safety reports.
- •Presence of an axillary temperature ≥ 37.5ºC, or acute symptoms greater than "mild" severity on the scheduled date of first vaccination.
- •Diagnosed with cancer, or treatment for cancer, within the past 3 years.
- •Any confirmed or suspected immunosuppressive or immunodeficient condition including history of human immunodeficiency virus (HIV) infection.
- •Chronic administration of immunosuppressants or other immune modifying drugs within 6 months of study enrolment or planned administration during the study period..
- •Any administration of a long-acting immune-modifying drug (within 3 months before study start, or a planned administration during the study period.
- •Receipt of any immunoglobulins and/or any blood products within 3 months of study enrolment or planned administration of any of these products during the study period.
- •Any significant disorder of coagulation or treatment with warfarin derivatives or heparin. Persons receiving individual doses of low molecular weight heparin outside of 24 hours prior to vaccination are eligible. Persons receiving prophylactic antiplatelet medications, e.g., low-dose aspirin, and without a clinically-apparent bleeding tendency, are eligible.
- •An acute evolving neurological disorder or history of Guillain-Barré syndrome.
- •Clinically or virologically confirmed influenza infection within 6 months preceding the study start.
- •Administration of any vaccines within 30 days before vaccination.
- •Any known or suspected allergy to any constituent of influenza vaccines; a history of anaphylactic-type reaction to any constituent of influenza vaccines; or a history of severe adverse reaction to a previous influenza vaccine.
- •Pregnant or lactating female
- •Female planning to become pregnant or planning to discontinue contraceptive precautions from study inclusion up to 2 months after completion of the vaccination series.
- •Any conditions which, in the opinion of the investigator, prevents the subjects from participating in the study.
结局指标
主要结局
Humoral Immune Response in Terms of Haemagglutination Inhibition (HI) Antibodies for Each Vaccine Strain, in Subjects Aged 18-60 and Above 60 Years
时间窗: 21 days after vaccination
次要结局
- Solicited Local and General Symptoms(During 7 days (Day 0 - Day 6) after vaccination)
- Number of Subjects Reporting Serious Adverse Events(During the whole study period (Day 0 - Day 182))
- Humoral Immune Response in Terms of HI Antibodies Against Each Vaccine Strain, at Different Timepoints in Subjects Aged 18-60 and Above 60 Years(At Days 0, 7 and 182)
- Potential Immune Mediated Diseases(During the whole study period (Day 0 - Day 182))
- Number of Subjects Reporting Unsolicited Adverse Events(During 31 days (Day 0 - Day 30) after vaccination)
研究者
研究点 (6)
Loading locations...
相似试验
已完成
3 期
Immunogenicity, Safety, Reactogenicity, Efficacy, Effectiveness and Lot Consistency of FluBlokInfluenzaNCT00539981Sanofi4,648
已完成
3 期
Fluarix Immunogenicity and Safety TrialInfluenzaNCT00100399National Institute of Allergy and Infectious Diseases (NIAID)1,050
已完成
3 期
Immunogenicity and Reactogenicity of Fluarix™ (Influsplit SSW®) 2007/2008 in People 18 Years Old or AboveInfluenzaNCT00476307GlaxoSmithKline120
已完成
3 期
A Study for Evaluation of Immunogenicity and Reactogenicity of Fluarix™ / Influsplit SSW® 2008/2009 in AdultsInfluenzaNCT00706563GlaxoSmithKline120
已完成
3 期
A Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' Seasonal Influenza Vaccine in AdultsInfluenzaNCT01144299GlaxoSmithKline114